tnt: treating to new targets

principal researchers

John LaRosa (State University of New York)

data custodian

Viatris Inc (originally Pfizer Inc.)

funding

Pfizer Inc.

key publications

• Design paper: Am J Cardiol 2004; 93: 154-158
• Main results: N Engl J Med 2005; 352: 1425-35
• Short-term abrupt statin discontinuation: Circulation 2004; 110: 2333-5 (302)
• Substantially lowering cholesterol: Diabetes Care 2006; 29: 1220-6 (303)
• High dose atorvastatin: J Am Coll Cardiol 2006; 48: 1793-9 (304)
• Reducing LDL cholesterol: Lancet 2006; 368: 919-28 (305)
• Safety and efficacy: Am J Cardiol 2007; 100(5): 747-52
• Effects on renal function: Clin J Am Soc Nephrol 2007; 2(6): 1131-9
• Effects in those over 65 years old: Ann Intern Med 2007; 147(1): 1-9
• Hospitalizations for heart failure: Circulation 2007; 115: 576-83 (309)
• HDL Cholesterol: N Engl J Med 2007; 357: 1301-10 (310)
• Previous percutaneous coronary intervention: Am J Cardiol 2008; 102: 1312-7 (311)
• Lipids, apolipoproteins, and their ratios: Circulation 2008; 117: 3002-9 (312)
• Effects by gender:  Heart 2008; 94(4): 434-9
• Chronic kidney disease: J Am Coll Cardiol 2008; 51: 1448-54 (314)
• Secondary prevention: J Am Coll Cardiol 2008; 51: 1938-43 (315)
• Blood pressure: J Clin Hypertens 2008; 10: 367-76. (316)
• Coronary artery disease, diabetes, and chronic kidney disease: Mayo Clin Proc 2008; 83: 870-9 (317)
• Plasma triglycerides and cardiovascular events: Am J Cardiol 2009; 104: 459-63 (230)
• Whole-genome and candidate gene analysis: Circ Cardiovasc Genet 2009; 2: 173-81 (318)
• Events after first event: Am J Cardiol 2010; 105: 283-7 (319)
• Heart rate at rest: Am J Cardiol 2010; 105: 905-11 (320)
• Genetic association of the CCR5 region: Circ Cardiovasc Genet 2010; 3: 162-8 (235)
• Blood pressure and CV events: Eur Heart J 2010; 31: 2897-908 (321)
• Impact of smoking: Am J Cardiol 2011; 107: 145-50 (238)
• 719Arg variant of KIF6: Circ Cardiovasc Genet 2012; 5: 51-7 (241)
• On treatment lipoprotein components: Eur J Clin Invest 2011; 41: 134-42 (322)
• GFR improvement: Am J Cardiol 2012; 109: 1761-6 (323)
• Inflammatory joint disease: Arthritis Rheum 2012; 64: 2836-46 (240)
• Residual risk in secondary prevention patients: Circulation 2012; 125: 1979-87 (324)
• Patients with ankylosing spondylitis and psoriatic arthritis: J Rheumatol 2012; 39: 1433-40 (325)
• Stable coronary artery disease: Circulation 2013; 127: 2485-93 (242)
• Effect of baseline risk factors for diabetes: J Am Coll Cardiol 2013; 61: 148-52 Erratum in: J Am Coll Cardiol 2014; 64: 1970 (243)
• Effect of change in body weight on incident diabetes mellitus: Am J Cardiol 2014; 113: 1593-8 Erratum in: Am J Cardiol 2015; 115: 1323 (326)
• Treatment-resistant hypertension: Am J Med. 2014; 127: 71-81.e1 (327)
• Treatment resistant hypertension: Eur Heart J 2014; 35(27): 1801-8 (328)
• Lipid and non-lipid biomarkers. PLoS One 2014; 9: e114519 (329)
• Risk of new-onset diabetes: J Am Coll Cardiol 2015; 65: 402-4 (245)
• Oxidized phospholipids on apolipoprotein B-100: J Am Coll Cardiol 2015; 65: 1286-95 (330)
• Low-density lipoprotein cholesterol variability: J Am Coll Cardiol 2015; 65: 1539-48 (331)
• Metabolic syndrome: Diabetes Obes Metab 2015; doi: 10.1111/dom.12581 (332)